AKT1 and breast carcinoma: These findings were consistent with those of previous reports that Lut and celecoxib combinatorial therapy protected against breast cancer cells (MDA-MB-231 and SkBr3) through activating ERK and inactivating AKT and through inactivating ERK and AKT in other breast cancer cells (MCF-7 and MCF7/HER18) [72].